X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (341) 341
index medicus (280) 280
clinical neurology (272) 272
multiple sclerosis (263) 263
female (147) 147
male (139) 139
neurology (132) 132
neurosciences (123) 123
adult (99) 99
middle aged (80) 80
multiple-sclerosis (67) 67
magnetic resonance imaging (60) 60
research (60) 60
risk factors (59) 59
care and treatment (52) 52
multiple sclerosis - drug therapy (51) 51
treatment outcome (51) 51
analysis (50) 50
disease (48) 48
multiple sclerosis, relapsing-remitting - drug therapy (47) 47
disease progression (46) 46
multiple sclerosis - immunology (45) 45
animals (43) 43
double-blind (41) 41
disability (40) 40
multiple sclerosis - epidemiology (40) 40
adolescent (39) 39
multiple sclerosis - diagnosis (39) 39
abridged index medicus (38) 38
aged (36) 36
multiple sclerosis - therapy (35) 35
risk (35) 35
young adult (33) 33
natalizumab (32) 32
placebo-controlled trial (32) 32
immunosuppressive agents - therapeutic use (31) 31
usage (31) 31
diagnosis (30) 30
immunology (30) 30
cerebrospinal-fluid (29) 29
multiple sclerosis - genetics (28) 28
patients (28) 28
clinical trials (27) 27
experimental autoimmune encephalomyelitis (27) 27
antibodies (26) 26
antibodies, monoclonal, humanized - therapeutic use (26) 26
health aspects (26) 26
time factors (26) 26
alemtuzumab (25) 25
disability evaluation (25) 25
immunologic factors - therapeutic use (25) 25
interferon-beta - therapeutic use (25) 25
medicine (25) 25
medicine & public health (25) 25
mice (25) 25
multiple sclerosis - physiopathology (25) 25
psychiatry (25) 25
research article (25) 25
therapy (25) 25
interferon (24) 24
medicine, general & internal (24) 24
double-blind method (23) 23
drug therapy (23) 23
interferon beta-1a (23) 23
safety (23) 23
association (22) 22
multiple sclerosis - pathology (22) 22
studies (22) 22
autoimmunity (21) 21
biomarkers (21) 21
central-nervous-system (21) 21
dosage and administration (20) 20
brain (19) 19
case-control studies (19) 19
cohort studies (19) 19
epstein-barr-virus (19) 19
follow-up studies (19) 19
neuroradiology (19) 19
brain - pathology (18) 18
child (18) 18
development and progression (18) 18
infection (18) 18
inflammation (18) 18
surgery (18) 18
efficacy (17) 17
epidemiology (17) 17
genetic aspects (17) 17
glatiramer acetate (17) 17
longitudinal studies (17) 17
lymphocytes (17) 17
prevalence (17) 17
t-cells (17) 17
cladribine (16) 16
interferon-beta (16) 16
interferon-beta - immunology (16) 16
multicenter (16) 16
multiple sclerosis - cerebrospinal fluid (16) 16
neurodegeneration (16) 16
population (16) 16
vitamin d (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 03/2012, Volume 83, Issue 3, pp. 298 - 304
Journal Article
British Medical Journal, ISSN 0959-8146, 01/2013, Volume 346, Issue 7892, p. 10
  Thompson and Giovannoni discuss the role of the drug industry in drug development, particularly in the repurposing of existing drugs. Although some... 
Drugs | Multiple sclerosis | Medical treatment | Pharmaceutical industry | Patients
Journal Article
Journal of Infection, ISSN 0163-4453, 07/2019, Volume 79, Issue 1, pp. 61 - 74
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 2/2018, Volume 24, Issue 2, pp. 222 - 226
Background: Neuroimaging studies have used magnetic resonance imaging-derived methods to assess brain volume loss in multiple sclerosis (MS) as a reliable... 
CLARITY | relapsing multiple sclerosis | disease progression | brain volume | cladribine | Brain atrophy | NEUROSCIENCES | CLINICAL NEUROLOGY | Atrophy | Neuroimaging | Multiple sclerosis | Magnetic resonance imaging | Tablets | Cladribine | Short Reports
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 10/2018, Volume 89, Issue 10, pp. A26 - A26
BackgroundThe CLARITY study demonstrated the benefit of cladribine tablets 3.5 mg/kg (CT3.5) for patients with relapsing MS (RMS). Patients with high disease... 
Population
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 10/2018, Volume 89, Issue 10, pp. A26 - A26
BackgroundCladribine tablets 3.5 mg/kg (CT3.5) demonstrated efficacy in patients with early (ORACLE-MS) and relapsing MS... 
Lymphocyte receptors | Lymphocytes
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 10/2018, Volume 89, Issue 10, pp. A25 - A26
BackgroundPatients with high disease activity (HDA) relapsing-remitting MS are less likely to attain no evidence of disease activity (NEDA; no relapses, MRI... 
Health risk assessment
Journal Article
Journal of Neurology, Neurosurgery and Psychiatry, ISSN 0022-3050, 12/2017, Volume 88, Issue 12
Journal Article
Journal of Neurology, Neurosurgery and Psychiatry, ISSN 0022-3050, 12/2017, Volume 88, Issue 12
Journal Article
Journal of Neurology, Neurosurgery and Psychiatry, ISSN 0022-3050, 12/2017, Volume 88, Issue 12
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 12/2017, Volume 88, Issue Suppl 1, pp. A52 - A52
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 10/2018, Volume 89, Issue 10, pp. A27 - A28
BackgroundCladribine tablets 3.5 mg/kg (CT3.5) demonstrated efficacy in RMS patients in CLARITY/CLARITY-Extension. Lymphopenia was common (CT3.5: mechanism of... 
Journal Article
by Kappos, Ludwig and Bar-Or, Amit and Cree, Bruce A C and Fox, Robert J and Giovannoni, Gavin and Gold, Ralf and Vermersch, Patrick and Arnold, Douglas L and Arnould, Sophie and Scherz, Tatiana and Wolf, Christian and Wallström, Erik and Dahlke, Frank and Achiron, Anat and Achtnichts, Lutz and Agan, Kadriye and Akman-Demir, Gulsen and Allen, Alison B and Antel, Jack P and Antiguedad, Alfredo Rodriguez and Apperson, Michelle and Applebee, Angela M and Ayuso, Guillermo Izquierdo and Baba, Masayuki and Bajenaru, Ovidiu and Balasa, Rodica and Balci, Belgin Petek and Barnett, Michael and Bass, Ann and Becker, Veit U and Bejinariu, Mihaela and Bergh, Florian Then and Bergmann, Arnfin and Bernitsas, Evanthia and Berthele, Achim and Bhan, Virender and Bischof, Felix and Bjork, Randall John and Blevins, Gregg and Boehringer, Matthias and Boerner, Thomas and Bonek, Robert and Bowen, James D and Bowling, Allen and Boyko, Alexey N and Boz, Cavit and Bracknies, Vera and Braune, Stefan and Brescia Morra, Vincenzo and Brochet, Bruno and Brola, Waldemar and Brownstone, Paul Kenneth and Brozman, Miroslav and Brunet, Donald and Buraga, Ioan and Burnett, Margaret and Buttmann, Mathias and Butzkueven, Helmut and Cahill, Jonathan and Calkwood, Jonathan C and Camu, William and Cascione, Mark and Castelnovo, Giovani and Centonze, Diego and Cerqueira, Joao and Chan, Andrew and Cimprichova, Andrea and Cohan, Stanley and Comi, Giancarlo and Conway, Jill and Cooper, Joanna A and Corboy, John and Correale, Jorge and Costell, Brian and Cottrell, David A and Coyle, Patricia K and Craner, Matthew and Cui, Liying and Cunha, Luis and Czlonkowska, Anna and da Silva, Ana Martins and de Sa, Joao and de Seze, Jérôme and Debouverie, Marc and Debruyne, Jan and Decoo, Danny and Defer, Gilles and Derfuss, Tobias and Deri, Norma H and Dihenia, Bhupesh and Dioszeghy, Peter and Donath, Vladimir and Dubois, Benedicte and Duddy, Martin and Duquette, Pierre and Edan, Gilles and Efendi, Husnu and Elias, Stanton and Emrich, Peter J and Estruch, Bonaventura Casanova and ... and EXPAND Clinical Investigators and Institute of Neuroscience and Physiology and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Institutionen för neurovetenskap och fysiologi
The Lancet, ISSN 0140-6736, 03/2018, Volume 391, Issue 10127, pp. 1263 - 1273
Journal Article